Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

S103 cells

Phase 1

XXijing Hospital

1

Indications

1

Total Trials

1

Active Trials

0

Competitors

Pipeline

Status by Indication[2][1]

Indication

Multiple Sclerosis (MS) Primary ProgressiveRecruiting

Multiple Sclerosis (MS) Primary ProgressivePhase 1

Recruiting

Timeline

Expected Milestones

Q4 2029

Phase 1Recruiting

Multiple Sclerosis (MS) Primary Progressive

NCT07587125

Clinical

Trials by Indication[1]

Multiple Sclerosis (MS) Primary Progressive1 trial

Safety and Efficacy of S103 Cells in Patients With Progressive or Refractory Multiple Sclerosis：An Open-Label, Single-Arm, Exploratory Clinical Study

Recruiting·XXijing Hospital·Phase 1·NCT07587125·9 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for S103 cells. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for S103 cells. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Xijing Hospital company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 1[1]
Company: XXijing Hospital

Related News